Shankar Siva
@_ShankarSiva
Followers
9K
Following
17K
Media
967
Statuses
7K
Radiation Oncologist at the Peter MacCallum Cancer Centre @petermaccc, Professor of Medicine, University of Melbourne, Australia 🇦🇺. Views are my own. #radonc
Melbourne, Victoria
Joined July 2012
1/ Thank you 🙏🏾, patients, families, and investigators, for contributing to the SEISMIC 🫁trial out now @LancetRespirMed - https://t.co/orK2owgN2T. Led by 🫁@DanSteinfort, this international multicentre recruited n=155 trial from 🇦🇺, 🇨🇦, 🇺🇸, 🇳🇱 #radonc @tssmn @PeterMacRadOnc
14
96
240
@_ShankarSiva @fcounago @DrAndrewLoblaw @Msaizguisasola @alongi_filippo @svporceddu @PeterMacRadOnc @CancerConnector Let’s go? I’m ready. Where are we going? 🚀
1
1
2
Custom gold bracelets — engraved with any name 🔥 Luxury shine • Hypoallergenic • Built to last. 20% OFF today only. Perfect gift. Premium look. CDORÉ
3
0
8
Tenemos el enorme orgullo de contar con el Dr. @_ShankarSiva en la Conferencia Magistral "El éxito de la SBRT en Cáncer Renal" #radioterapia #oncologíaradioterápica #simposioSEOR25 #SBRT #Cáncerrenal
1
3
9
If you haven’t heard yet #radonc - courtesy of Snr Ortega, owner/founder of @ZARA, 🇪🇸 is receiving 13 😍 proton machines as a donation to improve access to #radiotherapy. If only we had such philanthropy in Australia!!! 🦘🇦🇺🐨 @SEOR_ESP #simposioSEOR25
5
7
37
1/ Our new editorial asks whether MDT for OMD has been too often treated as a one-time upfront intervention. Have we overlooked the value of a comprehensive, longitudinal strategy—combining close surveillance with serial, strategic SABR when needed? 👉 https://t.co/ZQuYUMJaYR
2
16
34
🔋 Bimergen Energy $BESS Investor Webinar: 1 Week Away! Discover how Bimergen’s 2 GW battery storage pipeline positions it at the forefront of the U.S. energy transition. Tuesday, Nov. 11 | 4:15 PM ET Hear from leadership and join a live Q&A with the team. Reserve Your Spot
0
1
3
5 weeks left to register for @PeterMacCC #SABR2025! Expert discussions, interactive sessions, fantastic faculty @PeterMacRadOnc
@PBlanchardMD
@lauren_henke
@BarbaraJereczek
@DrewMoghanaki
@Melissa_O_Neil This always sells out, register soon! https://t.co/O3ooI3ddky
2
6
32
@cpeedell @gerryhanna @TheLancetOncol @DrewMoghanaki @finn_corinne @Mat_Guc @gwalls89 @HegiFiona @_ShankarSiva @MP_MacManus @drdavidpalma Great idea so much so that this trial actually already happened (SPRINT) and indeed chemotherapy-free radioimmunotherapy works quite well for the right patient! (Follow up trials in the works- @NitinOhri3 ) https://t.co/vAqcEpYtQR
pubmed.ncbi.nlm.nih.gov
Pembrolizumab and risk-adapted radiotherapy, without chemotherapy, are a promising treatment approach for patients with LA-NSCLC with a PD-L1 TPS of ≥50%.
0
3
15
No wonder the public have misconceptions about radiotherapy when you see a paper title such as this in @TheLancetOncol Shouldn’t it be Chemo-immunotherapy alone or without surgery or radiotherapy? #radonc
16
21
87
Federal investigators are taking a closer look at the Black Lives Matter Global Network Foundation’s finances. What could this probe mean for transparency, accountability, and the broader nonprofit sector?
11
15
107
Huge congratulations to Dr Muhammad Ali - winner of the Elekta Award at #RANZCR2025 for advances in the use of technology in #radiotherapy 🏆 Awarded for his Phase 2 RCT of Neoadj Pembro + #SABR before nephrectomy for #RCC (NAPSTER) @dr_alimuhammad @RANZCRcollege @PeterMacCC
1
6
36
🚨Important update from ProtecT #ProstateCancer trial after central pathology review 1️⃣ Which early PCa need treatment? Which do not? 2️⃣ For “bad” early PCa, do RP or RT prevent long-term (15y) metastasis? 🧵1/ @OncoAlert @urotoday @PCF_Science @JAMAOnc @Uroweb @AmerUrological
1/2 Just published in @JAMAOnc: 15-year outcomes of Active Monitoring, Surgery, and Radiotherapy for cribriform-positive and cribriform-negative prostate cancer in the ProtecT trial. Secondary analysis based on centralised biopsy review🔬 Article:
7
75
148
Thanks @myESMO @FAndreMD for a truly memorable Presidential Dinner at the magnificent Konzerthaus Berlin! Was an evening of elegance, inspiration, and friendship! So special to connect with colleagues and friends from 🌎 in this breathtaking venue! 🎶 @montypal @DrChoueiri
1
6
32
The RAMPART is thankfully positive making it the second adjuvant immunotherapy trial in #kidneycancer along with KN564 with Pembrolizumab. Driven by high risk group. Included non clear cell but should look at that subgroup more. Awaiting OS. #ESMO25 @OncoAlert
📣 #ESMO2025: n=565 🇬🇧🇪🇸🇦🇺🇫🇷 RAMPART RCT; Durvalumab + tremelimumab 📈boosts DFS in resected RCC #kidneycancer (HR 0.65, 2-yr 84% vs 78%), esp. in leibovich high-risk pts (HR 0.52, 81% vs 67%). G3+ AES 8% monitoring versus 40% with durva+treme. OS data eagerly awaited! #kcsm
0
15
30
Another study showing benefit of LCT for EGFR stage IV disease
📣 #ESMO25: NORTHSTAR RCT @YasirElaminMD; n=120 EGFR-mut #lungcancer osimertinib +/- LCT (68% #radiotherapy) ⬆️ 12-month PFS rate: 72% vs 54% ⬆️ PFS (25.3 vs 17.5 mo; HR 0.66; P=0.025) 😳 really not “oligo” population! ✅Grade ≥3 AEs: 29% (LCT arm) vs 22% (control) #radonc
0
3
5
💫🌟🟢 Live from #ESMO25 @OncoAlert @MedicalwatchHQ SBRT for Oligoprogression 👨⚕️ Speaker: Shankar Siva, MD PhD (@_ShankarSiva) 💡 Key takeaways: ➡️ SBRT provides a non-invasive, cost-effective alternative to metastasectomy — maintaining systemic therapy continuity and
0
33
55
A lot of good news on combined treatments including SBRT in RCC , great overview by @_ShankarSiva
#ESMO25
2
19
59
Great overview by @_ShankarSiva at #ESMO25 on the role of SABR/SBRT in oligoprogressive RCC SABR is safe, non-invasive, and allows continuation of systemic therapy without interruption Ongoing trials are actively exploring its synergy with systemic therapy @urotoday @OncoAlert
0
12
35
Embargo lifted. This weekend at @American_Heart Association Scientific Sessions our team will present “Single Lead ECG AI Model Accurately Predicts Moderate to Severe Hyperkalemia in Multi Hospital External Validation,” using AK+ Guard with Lead I ECG. Session info:
0
5
17
MDT Bridge just presented at #ESMO25 ➡️MDT-BRIDGE is 1st study to prospectively test neoadjuv IO+CT in patients with borderline resectable NSCLC ➡️95.2% of pts had either surgery or ChemoRT ➡️85.7% of pts had definitive resection ➡️Further follow-up is needed
1
14
27
🔥 NESCIO at #ESMO2025: Neoadjuvant ICI in ccRCC #kidneycancer 🌟 ARM A 6wks of nivolumab (closed), ARM B ipi+nivo or ARM C nivo+relatlimab; ➡️ARM B vs ARM C ⚪️7% vs 14% pathologic responses, ⚪️ 42.8% bs 14.2% Gr≥3 IR-AEs ⚪️ 35.7 % vs 28.6% Gr≥3 surgical AEs surgical. 🧐Not a
1
10
13